Amsterdam, June 19, 2013 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of the National Osteoporosis Guideline Group (NOGG) Update 2013 on diagnosis and management of osteoporosis in postmenopausal women and older men in the journal Maturitas.
Published in 2009 in Maturitas, the original guidelines have been highly cited and this update is timely with an additional focus on the management of glucocorticoid-induced osteoporosis, the role of calcium and vitamin D therapy and the benefits and risks of long-term bisphosphonate therapy. In all these areas, there have been new developments over the past few years that have had an impact on clinical practice and require modifications and/or additions to previous guidance.
The recommendations in the guidelines are intended to aid management decisions but do not replace the need for clinical judgement in the care of individuals in clinical practice.
These and other recommendations presented are published in the article:
"Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) Update 2013" by J.E. Compston, Claire Bowring, Alun Cooper, Cyrus Cooper, Cyril Davies, Roger M Francis, John A Kanis, David Marsh, Eugene V McCloskey, David M Reid and Peter Selby. The article appears as an article in press in Maturitas (June 2013), published by Elsevier.
Original guidelines published in 2009:
"Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK" by J. Compston, A. Cooper, C. Cooper, R. Francis, J.A. Kanis, D. Marsh, E.V. McCloskey, D.M. Reid, P. Selby, M. Wilkins, on behalf of the National Osteoporosis Guideline Group (NOGG). The article appears in Maturitas, Volume 62, Issue 2, (February 2009), published by Elsevier.
Notes for Editors
Full text of both articles are available to credentialed journalists upon request, contact firstname.lastname@example.org. For further details about the clinical guide or to contact the authors or EMAS, contact email@example.com or +31 20 485 3323
The National Osteoporosis Guideline Group (NOGG) was established to provide a clinical guideline for the management of men and women at high fracture risk, particularly to address the need to integrate the expression of a patient's fracture risk as a 10-year probability (the output from FRAX®) with current clinical management of osteoporosis. This included the need to define thresholds for bone mineral density measurement and treatment. http://www.shef.ac.uk/NOGG/index.html
Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond, publishing original research, reviews, consensus statements and guidelines. The scope encompasses all aspects of postreproductive health in both genders ranging from basic science to health and social care. http://www.maturitas.org/ http://www.journals.elsevier.com/maturitas
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.